Search

KR-102964974-B1 - METHOD, DEVICE AND SYSTEM FOR PROVIDING ERP SOLUTION FOR PHARMACEUTICAL RE-CONSIGNMENT SALES CONTRACT STATUS MANAGEMENT

KR102964974B1KR 102964974 B1KR102964974 B1KR 102964974B1KR-102964974-B1

Abstract

An apparatus according to one embodiment obtains information about a pharmaceutical company from a terminal of the pharmaceutical company, obtains information about a primary contractor from the terminal of the pharmaceutical company, generates a list of primary contractors based on the information about the primary contractor, stores the list of primary contractors by matching it with the pharmaceutical company, obtains information about a secondary contractor from the terminal of the primary contractor, generates a list of secondary contractors based on the information about the secondary contractors, stores the list of secondary contractors by matching it with the pharmaceutical company and the primary contractor, and repeatedly performs this for Nth contractors to list the hierarchical structure of contractors for the pharmaceutical company.

Inventors

  • 오성민

Dates

Publication Date
20260513
Application Date
20250304

Claims (3)

  1. In a method for providing an ERP solution for managing the status of pharmaceutical consignment sales contracts, performed by a device, A step of obtaining information about a pharmaceutical company from a pharmaceutical company terminal; A step of obtaining basic information about a primary consignee and contract information about the primary consignee from the terminal of the above pharmaceutical company; A step of generating a list of primary consignees based on basic information regarding the primary consignees and contract information regarding the primary consignees, and storing the list of primary consignees by matching it with pharmaceutical companies; A step of obtaining basic information regarding a second consignee and contract information regarding the second consignee from the terminal of the first consignee; A step of generating a list of secondary contractors based on basic information regarding the secondary contractors and contract information regarding the secondary contractors, and storing the list of secondary contractors by matching it with the pharmaceutical company and the primary contractor; and It includes the step of repeatedly performing on Nth-tier contractors to list the hierarchical structure of contractors for the pharmaceutical company, and After the step of listing the hierarchical structure of contractors for the aforementioned pharmaceutical company, A step of verifying the hierarchical structure of contractors for the above pharmaceutical company and selecting a contractor as a review contractor whose contract expiration date is within a pre-set standard period based on the current time; A step of obtaining the entrustment results for the aforementioned review outsourcing company; A step of checking whether the above commission result is lower than a preset first target result; If it is confirmed that the above entrustment result is lower than the above first target result, a step of sending an additional entrustment non-recommendation notification for the above review entrustment company to the terminal of the above pharmaceutical company and the terminal of the intermediate entrustment company that entrusted the above review entrustment company; If it is confirmed that the above commission result is not lower than the above first target result, a step of checking whether the above commission result is higher than a preset second target result; If it is confirmed that the above consignment result is higher than the above second target result, a step of sending an additional consignment recommendation notification for the review consignment company to the terminal of the pharmaceutical company and the terminal of the above intermediate consignment company; and If it is confirmed that the above entrustment result is not lower than the above first target result and is not higher than the above second target result, the method further includes the step of not sending additional entrustment non-recommendation notifications and additional entrustment recommendation notifications for the review entrustment company to the terminal of the pharmaceutical company and the terminal of the above intermediate entrustment company. If it is confirmed that the above entrustment result is higher than the above second target result, a step of sending an additional entrustment recommendation notification for the review entrustment company to the terminal of the pharmaceutical company and the terminal of the above intermediate entrustment company; subsequently, A step of checking whether additional entrustment to the aforementioned review entrustment company has been carried out, based on the fact that the current time is the expiration date of the entrustment to the aforementioned review entrustment company; A step of determining that additional outsourcing to the aforementioned review outsourcing company has been successfully completed if it is confirmed that additional outsourcing to the aforementioned review outsourcing company has been carried out; If it is confirmed that no additional entrustment to the aforementioned review outsourcing company has been carried out, a step of determining that the additional entrustment to the aforementioned review outsourcing company has failed and verifying the current commission rate for the aforementioned review outsourcing company; A step of verifying the average commission rate for the primary consignee matched with respect to the above pharmaceutical company; A step of determining whether the average commission rate for the above-mentioned primary consignee is higher than the current commission rate for the above-mentioned consignee under review; If it is confirmed that the above average commission rate is higher than the above current commission rate, the step of selecting the above review outsourcing company as the primary outsourcing company for the above pharmaceutical company via the terminal of the above pharmaceutical company, and sending a message to the above review outsourcing company recommending that additional outsourcing be carried out by providing the average commission rate for the above primary outsourcing company; If it is confirmed that the above average commission rate is not higher than the above current commission rate, a step of obtaining the maximum commission rate from the pharmaceutical company's terminal; A step of calculating an optimal commission rate based on the average commission rate for the above-mentioned first-tier consignment company, the average consignment result for the above-mentioned first-tier consignment company, and the consignment result for the above-mentioned review consignment company; A step of checking whether the above optimal fee rate is higher than the above maximum fee rate; A step of determining that further outsourcing to the aforementioned review outsourcing company is impossible if it is confirmed that the above optimal commission rate is higher than the above maximum commission rate; If it is confirmed that the above optimal commission rate is not higher than the above maximum commission rate, the method further includes the step of sending a message to the review outsourcing company via the pharmaceutical company's terminal recommending that they proceed with additional outsourcing by providing the above optimal commission rate; A step of repeatedly performing on Nth-tier contractors to list the hierarchical structure of contractors for the pharmaceutical company; subsequently, A step of identifying pharmacies that do not sell the pharmaceutical company's medicines as candidate pharmacies through a pharmacy database; A step of identifying the medicines currently being sold at the aforementioned candidate pharmacies, and identifying candidate pharmacies with sales volumes for competing medicines higher than a preset standard sales volume as pharmacies requiring entry; A step of identifying pharmacies included within a preset threshold distance based on the aforementioned pharmacy requiring entry as adjacent pharmacies; A step of checking whether there is a consignment company among the consignment companies matched with the above pharmaceutical company that supplies medicines to the above adjacent pharmacy; If it is confirmed that a consignment company supplying pharmaceuticals to the aforementioned adjacent pharmacy exists as a target consignment company, the step of transmitting a message to the terminal of the pharmaceutical company and the terminal of the target consignment company to supply the pharmaceuticals of the pharmaceutical company to the pharmacy requiring entry; and If it is confirmed that there is no consignment company selling pharmaceuticals at the aforementioned adjacent pharmacy, the method further includes the step of transmitting a message to the pharmaceutical company's terminal to supply the pharmaceutical company's pharmaceuticals to the pharmacy requiring entry. Method for providing an ERP solution for managing the status of pharmaceutical consignment sales contracts.
  2. In paragraph 1, After the step of listing the hierarchical structure of contractors for the aforementioned pharmaceutical company, A step of verifying the hierarchical structure of contractors for the above pharmaceutical company to determine whether there exists a duplicate contract contractor having multiple contract information for the above pharmaceutical company; If it is confirmed that the above-mentioned duplicate contract outsourcing company exists, a step of identifying the contract information regarding the above-mentioned duplicate contract outsourcing company as contract information requiring comparison; A step of verifying the commission rate through the commission agreement included in the above comparison-needed contract information; A step of selecting the contract information having the highest commission rate among the contract information requiring comparison as the maintenance contract information based on the above commission rate; A step of transmitting a duplicate contract notification regarding the pharmaceutical company to the terminal of the aforementioned duplicate contract consignee; A step of maintaining the maintenance contract information on the terminal of the aforementioned duplicate contract consignee and transmitting a recommendation message recommending the cancellation of the aforementioned contract information requiring comparison, excluding the aforementioned maintenance contract information; and If it is confirmed that the aforementioned duplicate contract outsourcing company does not exist, the step of determining that there is no duplicate contract with the aforementioned pharmaceutical company is further included. After the step of listing the hierarchical structure of contractors for the aforementioned pharmaceutical company, A step of querying the business registration status of a specific consignee included in the above hierarchy through a business information database at preset intervals; A step to check whether the above business registration status is closed; If the business registration status is confirmed to be closed, a step of transmitting a notification of the closure status regarding the specific consignee to the terminal of the specific consignee, and transmitting a notification of the closure status regarding the specific consignee and a contract confirmation notification regarding the specific consignee to the terminal of the pharmaceutical company and the terminal of the intermediate consignee that entrusted the specific consignee; If it is confirmed that the above business registration status is not in a closed state, a step of checking whether the above business registration status is in a suspended state; If the above business registration status is confirmed to be in a suspended state, a step of verifying the suspension period through the above business registration status; A step of identifying contract information regarding the aforementioned specific consignor as contract information requiring analysis, and verifying the consignment period through the consignment contract included in the contract information requiring analysis; A step of calculating a suspension rate based on the above suspension period and the above consignment period; A step of checking whether the above suspension rate is greater than a preset threshold rate; If it is confirmed that the above suspension rate is greater than the above threshold rate, a step of transmitting a suspension status notification for the specific consignor to the terminal of the specific consignor, and transmitting a suspension status notification for the specific consignor and a contract confirmation notification for the specific consignor to the terminal of the pharmaceutical company and the terminal of the intermediate consignor; If it is confirmed that the above suspension rate is not greater than the above threshold rate, the step of determining that there is no problem with the above suspension and not sending suspension status notifications and contract confirmation notifications; and If it is confirmed that the above business registration status is neither in a suspended state nor a closed state, the method further includes a step of determining that there is no problem with the above specific consignment company. Method for providing an ERP solution for managing the status of pharmaceutical consignment sales contracts.
  3. delete

Description

Method, Device, and System for Providing ERP Solution for Managing Pharmaceutical Re-consignment Sales Contract Status The present disclosure relates to a technology that provides an ERP solution to enable a pharmaceutical company to check and manage the contract status of its primary contractors, as well as secondary, tertiary, and other contractors. In the pharmaceutical industry, it is difficult for pharmaceutical companies to directly manage the entire distribution process, so it is common practice to sell medicines by utilizing multiple layers of contract manufacturers. Pharmaceutical companies enter into direct contracts with primary contractors, and primary contractors often re-entrust to secondary contractors. This process is repeated, forming a complex distribution structure involving multiple contractors, such as tertiary and quaternary contractors. However, this multi-level outsourcing structure is a factor that hinders management transparency from the perspective of pharmaceutical companies. In other words, pharmaceutical companies need to clearly understand the channels through which their medicines are delivered to end consumers, and to this end, they must store and monitor contract information concluded at each consignment stage. However, previously, while it was easy to manage up to the first-tier subcontractor, it was difficult to track the contract status in real time as one moved toward the second, third, and Nth-tier subcontractors, and it was impossible to respond immediately when problems such as contract duplication, legal issues, or failure to meet sales targets occurred. In addition, there were issues such as contracts continuing with some outsourcing companies even after they had gone out of business, or unnecessary duplicate fees arising from entering into multiple contracts with the same pharmaceutical company. Furthermore, if a specific contractor maintains a contract for a certain period but exhibits poor actual sales performance, pharmaceutical companies must detect this in advance and review whether to re-contract; however, it was difficult to automate this process using existing manual methods. Accordingly, the need has arisen for an Enterprise Resource Planning (ERP) solution capable of systematically managing all contract information concluded during the outsourcing and sub-outsourcing processes, and detecting and analyzing contractual issues in real time. FIG. 1 is a schematic diagram showing the configuration of a system according to one embodiment. FIG. 2 is a flowchart illustrating the process of providing an ERP solution for managing the status of pharmaceutical consignment sales contracts according to one embodiment. FIG. 3 is a flowchart illustrating the process of checking whether there is a duplicate contract for a pharmaceutical company according to one embodiment. FIG. 4 is a flowchart illustrating the process of periodically verifying the registration status of a consignee according to one embodiment to detect temporary or permanent closure. FIG. 5 is a flowchart for explaining the process of deciding on additional entrustment at the time of entrustment expiration through the entrustment results according to one embodiment. FIG. 6 is a flowchart for explaining the process of verifying additional consignment progress according to one embodiment. FIG. 7 is a flowchart illustrating the process of a pharmaceutical company recommending a new pharmacy to enter and requesting supply from a consignee according to one embodiment. FIG. 8 is an example diagram of the configuration of a device according to one embodiment. Hereinafter, embodiments are described in detail with reference to the attached drawings. However, various modifications may be made to the embodiments, and thus the scope of the patent application is not limited or restricted by these embodiments. It should be understood that all modifications, equivalents, and substitutions to the embodiments are included within the scope of the rights. Specific structural or functional descriptions of the embodiments are disclosed for illustrative purposes only and may be modified and implemented in various forms. Accordingly, the embodiments are not limited to the specific disclosed forms, and the scope of this specification includes modifications, equivalents, or substitutions that fall within the technical concept. Terms such as "first" or "second" may be used to describe various components, but these terms should be interpreted solely for the purpose of distinguishing one component from another. For example, the first component may be named the second component, and similarly, the second component may be named the first component. When it is stated that a component is "connected" to another component, it should be understood that it may be directly connected to or joined to that other component, or that there may be other components in between. The terms used in the embodiments are for illustrative purposes only an